Lowers the risk of cardiovascular mortality. Sold as Lopressor. Every FDA application for this active ingredient: 4 branded and 33 generic. Boxed warning
As of Nov 22, 2026, FDA lists 37 applications for Metoprolol tartrate (sold as Lopressor), first approved Aug 7, 1978, with 3 new uses approved and 1 published complete response letter.
| Aug 7, 1978 | LopressorNDA 17963 · New molecular entity | Validus Pharmaceuticals | 61 | Marketed |
| Mar 30, 1984 | LopressorNDA 18704 · New dosage form | Novartis Pharmaceuticals | 23 | Discontinued |
| Dec 21, 1993 | Metoprolol TartrateANDA 73654 | Sun Pharmaceutical Industries | 23 | Discontinued |
| Dec 21, 1993 | Metoprolol TartrateANDA 73666 | PharmoBedient | 5 | Discontinued |
| Dec 21, 1993 | Metoprolol TartrateANDA 74032 | Watson Laboratories | 3 | Discontinued |
| Dec 21, 1993 | Metoprolol TartrateANDA 74133 | Hospira | 16 | Discontinued |
| Jan 27, 1994 | Metoprolol TartrateANDA 74333 | Teva Pharmaceuticals | 2 | Discontinued |
| Jan 27, 1994 | Metoprolol TartrateANDA 74258 | Apothecon | 4 | Discontinued |
| Mar 25, 1994 | Metoprolol TartrateANDA 73288 | Chartwell RX | 22 | Discontinued |
| Mar 25, 1994 | Metoprolol TartrateANDA 73289 | Chartwell RX | 19 | Discontinued |
| May 27, 1994 | Metoprolol TartrateANDA 74217 | Watson Laboratories | 13 | Discontinued |
| Sep 30, 1994 | Metoprolol TartrateANDA 74143 | Teva Pharmaceutical Industries | 6 | Discontinued |
| Jan 31, 1995 | Metoprolol TartrateANDA 74141 | Heritage Pharmaceuticals | 20 | Discontinued |
| Apr 27, 1995 | Metoprolol TartrateANDA 74453 | Adaptis | 3 | Marketed |
| Dec 10, 1996 | Metoprolol TartrateANDA 74644 | Sun Pharmaceutical Industries | 14 | Marketed |
| Jul 6, 1998 | Metoprolol TartrateANDA 75160 | Hospira | 11 | Discontinued |
| Jul 7, 2003 | Metoprolol TartrateANDA 76495 | Hikma Pharmaceuticals | 4 | Marketed |
| Jan 15, 2004 | Metoprolol TartrateANDA 76670 | Sun Pharmaceutical Industries | 10 | Discontinued |
| Jan 16, 2004 | Metoprolol TartrateANDA 76704 | Mylan | 8 | Marketed |
| May 30, 2007 | Metoprolol TartrateANDA 77761 | Hikma Farmacêutica | 7 | Marketed |
| Sep 11, 2007 | Metoprolol TartrateANDA 77739 | Aurobindo Pharma | 9 | Marketed |
| Oct 2, 2007 | Metoprolol TartrateANDA 77360 | Sandoz | 7 | Marketed |
| Apr 29, 2008 | Metoprolol TartrateANDA 78085 | Hospira | 7 | Marketed |
| Jun 17, 2008 | Metoprolol TartrateANDA 78459 | Ipca Laboratories | 5 | Marketed |
| Sep 30, 2009 | Metoprolol TartrateANDA 90386 | Am Regent | 3 | Discontinued |
| Apr 19, 2010 | Metoprolol TartrateANDA 90317 | OneSource Specialty | 5 | Discontinued |
| Oct 25, 2010 | Metoprolol TartrateANDA 91045 | Fresenius Kabi USA | 3 | Marketed |
| Dec 29, 2010 | Metoprolol TartrateANDA 91307 | Luitpold Pharmaceuticals | 1 | Discontinued |
| Apr 29, 2013 | Metoprolol TartrateANDA 78950 | Baxter Healthcare | 3 | Marketed |
| May 28, 2013 | Metoprolol TartrateANDA 202871 | Alembic Pharmaceuticals | 1 | Marketed |
| Aug 27, 2014 | Metoprolol TartrateANDA 204205 | Gland Pharma | 1 | Marketed |
| Oct 28, 2014 | Metoprolol TartrateANDA 200981 | Rubicon Research | 3 | Marketed |
| Feb 5, 2020 | Metoprolol TartrateANDA 208955 | ScieGen Pharmaceuticals | 0 | Marketed |
| Apr 19, 2023 | Metoprolol TartrateANDA 212402 | Zydus Pharmaceuticals (USA) | 2 | Discontinued |
| Apr 10, 2025 | LopressorNDA 219373 · New dosage form | Rubicon Research | 1 | Marketed |
| Aug 28, 2025 | LopressorNDA 218698 · New formulation or manufacturer | XTM Consulting | 1 | Marketed |
| — | Metoprolol TartrateANDA 74380 | Purepac Pharmaceutical | 0 | Discontinued |
| Letter | Product | Now |
|---|---|---|
| Jun 12, 2024 | NDA 218698Product Quality | Unapproved |
| Metoprolol Tartrate | Part D | $107M | 0% | 3,744,789 |
| Lopressor | Part D | $298K | −4% | 272 |
| METOPROLOL TARTRATE | Part B | $1K | New | 1,065 |
Of the 32 whose ending is known, 47% met their primary endpoint, 3% missed it and 50% stopped early.
| An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 SubstratesUlcerative Colitis, Crohn's Disease · Sanofi | Phase 1 | Not yet recruiting | Nov 6, 2026 |
| BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic CardiomyopathyCardiomyopathy, Hypertrophic Obstructive · Braveheart Bio, Inc. | Phase 3 | Recruiting | Aug 10, 2026 |
| Predicting Response and Exposure Changes in Cirrhosis for EffectivenessLiver Cirrhosis · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Not applicable | Not yet recruiting | Aug 6, 2026 |
| Comparing Two Heart Medicines for Fast, Irregular Heartbeat (Atrial Fibrillation)Atrial Fibrillation (AF), Atrial Fibrillation With Rapid Ventricular Response · Muhammad Ali Javed | Phase 4 | Not yet recruiting | Jul 15, 2026 |
| MAGNEsium With meToprolol for Rate Control In Atrial FibrillationAtrial Flutter With Rapid Ventricular Response · Wake Forest University Health Sciences | Phase 3 | Recruiting | Jun 8, 2026 |
| Beta-Blockers on Neoadjuvant Immunochemotherapy for Hypertensive Patients With Gastric CancerGastric Cancer (GC) · Nanfang Hospital, Southern Medical University | — | Active, not recruiting | Jun 3, 2026 |
| Dose-Response Interaction of Metoprolol and Sufentanil for Attenuating Hemodynamic Responses in Tracheal IntubationGeneral Anesthesia; Tracheal Intubation · Fujian Provincial Hospital | Phase 4 | Not yet recruiting | May 19, 2026 |
| Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite AthletesSafety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes · Enhanced Emirates Limited | Not applicable | Enrolling by invitation | May 6, 2026 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA